All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
8.5 Targeted antineoplastics
Toggle Pages
8.5.1 Epidermal growth factor receptor (EGFR) inhibitors
8.5.2 Human epidermal growth factor receptor (HER2) inhibitors
8.5.3 Histone deacetylase (HDAC) inhibitors
8.5.4 Immunomodulatory agents (IMiDs)
8.5.5 Mammalian target of rapamycin (mTOR) inhibitors
8.5.6 Mitogen-activated protein kinase (MAPK) inhibitors
8.5.7 Mitotic inhibitors
8.5.8 Monoclonal antibodies
8.5.9 Multikinase inhibitors
8.5.10 Proteasome inhibitors
8.5.11 Retinoids
8.5.12 Tyrosine kinase inhibitors
8.5.13 VEGF / VEGFR inhibitors
Chapter 8: Immunomodulatory treatments and malignant disease
Toggle Parent Pages
Print this page
Patients on chemotherapy at home
The Cancer Drugs Fund (CDF)
8.1 Selective internal radiation therapy (SIRT)
8.2 Drugs affecting the immune response
8.3 Sex hormones and hormone antagonists in malignant disease
8.4 Cytotoxic antineoplastics
8.5 Targeted antineoplastics
8.6 Miscellaneous antineoplastics
Page last updated:
5 January 2022
Contact us about this page
8.5.3 Histone deacetylase (HDAC) inhibitors
First Line
Second Line
Specialist
Hospital Only
Panobinostat lactate anhydrous
- Capsules 10mg, 15mg, 20mg
Notes
- NICE TA380: Panobinostat (Farydak) in combination with bortezomib and dexamethasone is recommended, within its marketing authorisation, as an option for treating multiple myeloma, that is, for 'adult patients with relapsed and/or refractory multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent' when the company provides panobinostat with the discount agreed in the patient access scheme (January 2016).
